BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25217227)

  • 1. Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit.
    Lo Cascio G; Koncan R; Stringari G; Russo A; Azzini A; Ugolini A; Ligozzi M; Polati E; Cornaglia G; Concia E; Schweiger V
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):357-65. PubMed ID: 25217227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of 1,3-beta-D glucan for diagnosis of invasive fungal infections in hematooncological patients: usefulness for screening of invasive mycosis and for confirmation of galactomannan positive results].
    Rácil Z; Kocmanová I; Weinbergerová B; Winterová J; Lengerová M; Hrncírová K; Mayer J
    Klin Mikrobiol Infekc Lek; 2009 Apr; 15(2):48-57. PubMed ID: 19488961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.
    Koo S; Baden LR; Marty FM
    Clin Microbiol Infect; 2012 May; 18(5):E122-7. PubMed ID: 22404638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Values and Limitations of (1,3)-β-D-Glucans and Galactomannan Assays for Invasive Fungal Infection in Patients Admitted to Pediatric Intensive Care Unit.
    Zheng F; Zha H; Yang D; Deng J; Zhang Z
    Mycopathologia; 2017 Apr; 182(3-4):331-338. PubMed ID: 27664106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.
    Pini P; Bettua C; Orsi CF; Venturelli C; Forghieri F; Bigliardi S; Faglioni L; Luppi F; Serio L; Codeluppi M; Luppi M; Mussini C; Girardis M; Blasi E
    Infection; 2016 Apr; 44(2):223-33. PubMed ID: 26475482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.
    Senn L; Robinson JO; Schmidt S; Knaup M; Asahi N; Satomura S; Matsuura S; Duvoisin B; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2008 Mar; 46(6):878-85. PubMed ID: 18260755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies.
    Azoulay E; Guigue N; Darmon M; Mokart D; Lemiale V; Kouatchet A; Mayaux J; Vincent F; Nyunga M; Bruneel F; Rabbat A; Bretagne S; Lebert C; Meert AP; Benoit D; Pene F
    Oncotarget; 2016 Apr; 7(16):21484-95. PubMed ID: 26910891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial.
    Bloos F; Held J; Schlattmann P; Brillinger N; Kurzai O; Cornely OA; Thomas-Rüddel D
    Trials; 2018 Sep; 19(1):472. PubMed ID: 30180873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors.
    Hammarström H; Kondori N; Friman V; Wennerås C
    Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):917-25. PubMed ID: 25573536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
    Cento V; Alteri C; Mancini V; Gatti M; Lepera V; Mazza E; Moioli MC; Merli M; Colombo J; Orcese CA; Bielli A; Torri S; Gasparini LE; Vismara C; De Gasperi A; Brioschi P; Puoti M; Cairoli R; Lombardi G; Perno CF
    Mycoses; 2020 Dec; 63(12):1299-1310. PubMed ID: 32810888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever.
    Ellis M; Al-Ramadi B; Finkelman M; Hedstrom U; Kristensen J; Ali-Zadeh H; Klingspor L
    J Med Microbiol; 2008 Mar; 57(Pt 3):287-295. PubMed ID: 18287290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index.
    Posteraro B; De Pascale G; Tumbarello M; Torelli R; Pennisi MA; Bello G; Maviglia R; Fadda G; Sanguinetti M; Antonelli M
    Crit Care; 2011; 15(5):R249. PubMed ID: 22018278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting.
    Mohr JF; Sims C; Paetznick V; Rodriguez J; Finkelman MA; Rex JH; Ostrosky-Zeichner L
    J Clin Microbiol; 2011 Jan; 49(1):58-61. PubMed ID: 21048005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of (1,3)-beta-D-glucan to diagnosis of invasive candidiasis after liver transplantation.
    Levesque E; El Anbassi S; Sitterle E; Foulet F; Merle JC; Botterel F
    J Clin Microbiol; 2015 Mar; 53(3):771-6. PubMed ID: 25520448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.
    Martín-Mazuelos E; Loza A; Castro C; Macías D; Zakariya I; Saavedra P; Ruiz-Santana S; Marín E; León C
    Intensive Care Med; 2015 Aug; 41(8):1424-32. PubMed ID: 26134359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients.
    Presterl E; Parschalk B; Bauer E; Lassnigg A; Hajdu S; Graninger W
    Int J Infect Dis; 2009 Nov; 13(6):707-12. PubMed ID: 19157947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The significance of serum GM and BG antigens assay for invasive fungal infections in hematological malignancies patients].
    Zeng SY; Liu T; Meng WT; Chen YN
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):43-6. PubMed ID: 21429401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.
    Ostrosky-Zeichner L; Alexander BD; Kett DH; Vazquez J; Pappas PG; Saeki F; Ketchum PA; Wingard J; Schiff R; Tamura H; Finkelman MA; Rex JH
    Clin Infect Dis; 2005 Sep; 41(5):654-9. PubMed ID: 16080087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections.
    Del Bono V; Delfino E; Furfaro E; Mikulska M; Nicco E; Bruzzi P; Mularoni A; Bassetti M; Viscoli C
    Clin Vaccine Immunol; 2011 Dec; 18(12):2113-7. PubMed ID: 21994353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.
    Martínez-Jiménez MC; Muñoz P; Valerio M; Vena A; Guinea J; Bouza E
    J Antimicrob Chemother; 2015 Nov; 70(11):3107-15. PubMed ID: 26311840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.